Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
40.6M
-
Number of holders
-
127
-
Total 13F shares, excl. options
-
22M
-
Shares change
-
+2.24M
-
Total reported value, excl. options
-
$937M
-
Value change
-
+$93.6M
-
Put/Call ratio
-
0
-
Number of buys
-
69
-
Number of sells
-
-46
-
Price
-
$42.70
Significant Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) as of Q1 2023
146 filings reported holding KROS - Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q1 2023.
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) has 127 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 22M shares
of 40.6M outstanding shares and own 54.16% of the company stock.
Largest 10 shareholders include FMR LLC (4.05M shares), ORBIMED ADVISORS LLC (1.68M shares), ALKEON CAPITAL MANAGEMENT LLC (1.68M shares), BlackRock Inc. (1.68M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.15M shares), VANGUARD GROUP INC (1.05M shares), STATE STREET CORP (944K shares), Paradigm Biocapital Advisors LP (931K shares), Candriam S.C.A. (745K shares), and Nantahala Capital Management, LLC (743K shares).
This table shows the top 127 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.